GlassScriptPhysician profile
Eric M Sellers
NPI 1720468523
$32,377.42
in general payments reported to CMS, 2019-2025
37 companies · $11K in 2025
The $11K reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $853 · 2022: $2,687 · 2023: $3,045 · 2024: $15K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Food and Beverage: $9,908 · Travel and Lodging: $2,061 · Education: $98.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,770.00 |
| Food and Beverage | $9,908.18 |
| Travel and Lodging | $2,060.57 |
| Education | $98.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $19,806.06 | 2024-2025 | Voquezna |
| Abbvie INC. | $2,581.39 | 2021-2025 | Linzess, Rinvoq, Skyrizi |
| Boston Scientific Corporation | $1,587.71 | 2022-2025 | Spyglass, General - Biliary Devices, Axios |
| Takeda Pharmaceuticals U.S.A., INC. | $1,319.94 | 2021-2024 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,183.77 | 2021-2025 | Stelara, Tremfya, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $916.05 | 2021-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $710.93 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $576.45 | 2021-2024 | |
| Genzyme Corporation | $563.33 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $472.98 | 2021-2024 | Zeposia |
| Celgene Corporation | $351.88 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $302.54 | 2022-2024 | Dupixent |
| Medtronic, INC. | $204.69 | 2023 | Gi Genius |
| Pfizer INC. | $193.59 | 2022-2024 | |
| Ardelyx, INC. | $174.79 | 2022-2025 | Ibsrela |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ethicon US, LLC | $150.00 | 2024 | Linx Reflux Management System |
| Organon LLC | $140.82 | 2021-2024 | Renflexis, Hadlima |
| Conmed Corporation | $130.38 | 2023 | Conmed Biliary, Conmed Generators, Conmed Hemostasis |
| Redhill Biopharma INC. | $125.83 | 2021-2023 | Movantik, Talicia, Aemcolo |
| Intercept Pharmaceuticals, INC. | $118.98 | 2022-2025 | Ocaliva |
| Fisher & Paykel Healthcare INC | $117.30 | 2025 | Fisher & Paykel Healthcare |
| Fresenius Kabi USA, LLC | $108.77 | 2023 | Idacio |
| Madrigal Pharmaceuticals | $69.79 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $67.00 | 2022-2024 | Suflave |
| Echosens North America, INC. | $54.61 | 2024 | Fibroscan |
| Micro-Tech Endoscopy USA, INC. | $49.20 | 2023-2024 | Dat Device, Blueboost |
| Janssen Scientific Affairs, LLC | $45.18 | 2025 | Tremfya, Stelara |
| Novo Nordisk INC | $39.55 | 2024 | Wegovy |
| Merck Sharp & Dohme LLC | $37.34 | 2023 | Dificid |
| Nestle Healthcare Nutrition INC. | $33.89 | 2021-2022 | |
| Daiichi Sankyo INC. | $29.43 | 2022 | |
| Exact Sciences Corporation | $23.94 | 2024 | |
| Olympus America INC. | $20.85 | 2021 | |
| Mylan Institutional INC. | $20.30 | 2023 | |
| Qol Medical, LLC | $20.28 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.19 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $13.69 | 2024 | Iqirvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Sellers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.